A Randomized, Open-Label, Multicenter Study of VELCADE With Rituximab or Rituximab Alone in Subjects With Relapsed or Refractory, Rituximab Naive or Sensitive Follicular B-Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase III
Latest Information Update: 02 Apr 2013
At a glance
- Drugs Bortezomib (Primary) ; Rituximab
- Indications Follicular lymphoma
- Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
- 09 Dec 2011 Results will be presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology, according to a Janssen-Cilag media release.
- 12 Jun 2011 Patient-reported quality-of-life outcomes presented at the 16th Congress of the European Hematology Association.
- 12 Jun 2011 Primary endpoint 'Progression-free-survival-duration' has been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History